针对针对癌症管理的线粒激素Eg5的目标化合物的非基优化用于癌症管理
Damilola S Bodun1,2,3, Damilola A Omoboyowa1, Victor F Olofinlade4
1Phyto-medicine and Computational Biology Laboratory, Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Ondo State Nigeria.
这项研究通过计算药物设计确定了五种强大的人类EG5抑制剂,显示了癌症治疗开发的前景. 建议进一步进行体外和体内验证.
科学领域:
- 药用化学 医学化学
- 计算机化药物设计技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 优化对于药物开发至关重要.
- 之前的in silico研究发现了与参考药物相比具有更高的结合亲和力和稳定性的命中化合物.
研究的目的:
- 为潜在的治疗应用产生和选新型化合物中的新型类似物.
- 为了确定人类EG5 (癌症治疗中的关键目标) 的强效抑制剂.
主要方法:
- 使用遗传算法生成了12500个类似物.
- 用于虚拟选的定量结构-活动关系 (QSAR) 建模.
- 利用分子对接,MMGBSA,诱导适合对接和量子极化联体对接来评估顶级模拟物.
- 进行ADMET预测和分子动力学 (MD) 模拟,以评估稳定性.
主要成果:
- 确定了五种主要类型 (化合物9794,8592,9786,2744,3246) 与人体Eg5强烈结合.
- 顶级类似物显示出显著的结合能和与关键残留物的相互作用 (GLU 116,GLU 117,ARG 119).
- MMGBSA分析表明与共结晶的配体相似的亲缘关系;化合物9786通过诱导适合对接显示出更高的疗效.
- ADMET预测表明有利的药理特性 (HIA阳性,非致癌);MD模拟证实了稳定性.
结论:
- 综合计算策略成功识别了有前途的人体Eg5抑制剂.
- 前五个类型显示出进一步开发抗癌疗法的巨大潜力.
- 为了验证这些候选药物的疗效,需要进行体外和体内研究.
更多相关视频
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
相关概念视频
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Destabilization of Microtubules
Drugs that Stabilize Microtubules
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
